Stock MPIT MEDICAL PROGNOSIS INSTITUTE A/S
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights Medical Prognosis Institute A/S Nasdaq Copenhagen

Equities

MPIT

DK0060732477

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Premarket Gainers
MT
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic
CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology
CI
Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic for Dovitinib in the Peer-Reviewed Journal PLOS ONE
CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Allarity Therapeutics, Inc. and Detsamma Investments Pty. Ltd. Announce Collaboration to Support Clinical Development of Deflexifol? with DRP® Companion Diagnostics
CI
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol with DRP Companion Diagnostics
CI
Allarity Therapeutics, Inc. Announces Initial Results from Its European Phase 2 Clinical Trial Evaluating the Efficacy of Ixempra®? in Metastatic Breast Cancer Patients
CI
Allarity Therapeutics, Inc. Announces Results of Prospective Phase 2 Clinical Study
CI
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Allarity Therapeutics, Inc. Accelerates Trial Enrollment to Bring Fda-Approves Breast Cancer Treatment to European Market - Interim Results Could Be Released in Second Half of 2023
CI
Allarity Therapeutics Doses Its First Patient in Phase 1B of Its Clinical Trial for the Novel Combination Therapy of Two Drugs, Stenoparib and Dovitinib
CI
Allarity Therapeutics, Inc. Allarity's DRP Companion Diagnostic for Cisplatin Accepted At 2023 ASCO Annual Meeting
CI
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
CI
Allarity Therapeutics, Inc. Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALLR Stock
  4. MPIT Stock
  5. News Medical Prognosis Institute A/S
  6. Highlights